Abstract
Background and Aims: L-homoarginine (hArg) is a nonproteinogenic amino acid that recently has been shown to be inversely correlated with adverse cardiovascular outcomes. In particular, low circulating hArg was associated with biochemical and clinical characteristics of heart failure. A clinical trial with hArg supplementation in healthy volunteers demonstrated four- and sevenfold increase of hArg plasma levels after the single oral dose of 125 mg without any adverse effects. We propose a prospective clinical study to assess if hArg supplementation improves outcomes in patients with HFpEF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
